secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001493152-23-007127
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Cell Therapeutics Q4 net loss $6.4M, revenue $1.9M; cash $57.9M; pipeline advances
--------------------------------------------------------------------------------

- Q4 2022 net loss $6.4M ($0.03/sh), revenue $1.9M; FY2022 net loss $26.3M ($0.15/sh), revenue $14.7M.
- Cash and securities $57.9M at Dec 31, 2022; expected to fund planned operations into Q3 2024.
- Genentech initiated Phase 2a study of RG6501 (OpRegen) for geographic atrophy; RMAT and pre-IND submitted for OPC1 and VAC2.
- Launched two new cell therapy programs for hearing/vision loss; appointed Jill Howe as CFO in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000149315223007127/0001493152-23-007127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000149315223007127/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-007127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer